VIVUS gains NDA approval for TA-1790 in the US

May 7, 2012 PRESS RELEASE Mitsubishi Tanabe Pharma Corporation VIVUS gains NDA approval for TA-1790 in the US VIVUS (head office: Mountain View, Californi a, U.S.) announced on April 27, 2012, that the company obtained NDA approval in the United States for TA -1790 (generic name: avanafil), a phosphodiesterase type5 (PDE5) inhibitor, which the company has developed as a treatment of erectile dysfunction (ED). TA-1790 was discovered for the treatment of ED by Mitsubishi Tanabe Pharma Corporation, (Head office: Osaka, Japan) which is expected to have a quick onset and fewer side effects. In February 2001, Mitsubishi Tanabe Pharma licensed the devel opment and marketing rights of the compound out to VIVUS for the entire world excluding Japan and a certain part of Asia. VIVUS will commercialize it under the brand name Stendra TM in the US. In Europe, MAA was filed by VIVUS with TA-1790 as a treatment of ED in March, 2012, and in South Korea, it is approved, and has been marketed by JW Pharma (Head office: Seoul, Korea) under the brand name Zepeed® from October, 2011. <Media enquiry> Corporate Communications Department Phone: +81 6-6205-5211

The release as fetched from its publisher. tanabe-pharma.com ↗